XOMA's (XOMA) Buy Rating Reiterated at HC Wainwright

XOMA (NASDAQ:XOMA - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $104.00 price target on the biotechnology company's stock. HC Wainwright's target price would indicate a potential upside of 322.25% from the stock's previous close. HC Wainwright also issued estimates for XOMA's Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.39 EPS, FY2025 earnings at $0.62 EPS and FY2026 earnings at $1.16 EPS.

Other analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of XOMA from a "sell" rating to a "hold" rating in a report on Friday, April 11th. Benchmark started coverage on shares of XOMA in a research note on Thursday, April 17th. They set a "buy" rating and a $35.00 target price on the stock.

XOMA Price Performance

NASDAQ XOMA traded down $0.87 on Wednesday, reaching $24.63. 13,916 shares of the company's stock traded hands, compared to its average volume of 31,096. The stock has a market cap of $294.75 million, a PE ratio of -7.08 and a beta of 0.89. XOMA has a 12 month low of $18.35 and a 12 month high of $35.00. The stock has a 50-day simple moving average of $22.93 and a 200 day simple moving average of $25.06. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

XOMA (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.32. The firm had revenue of $15.91 million during the quarter, compared to the consensus estimate of $6.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. As a group, research analysts predict that XOMA will post -1.41 earnings per share for the current year.

Insider Activity

In other XOMA news, CEO Owen Hughes sold 25,637 shares of the business's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total value of $650,667.06. Following the sale, the chief executive officer now directly owns 62,701 shares of the company's stock, valued at approximately $1,591,351.38. The trade was a 29.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $27.10, for a total value of $10,642,793.30. Following the completion of the sale, the insider now directly owns 1,267,545 shares in the company, valued at approximately $34,350,469.50. This represents a 23.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders bought a total of 29,312 shares of company stock worth $735,061 in the last quarter. 9.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On XOMA

Several large investors have recently modified their holdings of XOMA. GAMMA Investing LLC lifted its position in XOMA by 1,063.8% in the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 1,585 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 800 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after purchasing an additional 1,183 shares in the last quarter. Deutsche Bank AG raised its stake in shares of XOMA by 5,087.9% in the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 6,309 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after purchasing an additional 2,009 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.